VENU+ Brings Next-Generation Guest Experience Technology to Al Shallal Theme Park
17.6.2026 12:00:00 CEST | Business Wire | Press release
First Saudi Arabian deployment of VENU+’s GoPod locker technology supports continued Middle East expansion and growing demand for modern attraction infrastructure
VENU+, a leading global provider of tech-enabled guest mobility, storage, and entertainment solutions today announced the upcoming deployment of its GoPod® Locker technology platform at Al Shallal Theme Park, one of Saudi Arabia’s most recognized amusement destinations. VENU+ is backed by ZCG Private Equity, the private equity arm of Z Capital Group (“ZCG”), a privately held global firm.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617240101/en/
The installation, scheduled to go live in Summer 2026, marks VENU+’s first customer deployment in the Kingdom of Saudi Arabia and represents another milestone in the company’s accelerating global expansion across high-growth tourism and entertainment markets.
Located in the heart of Jeddah near the city’s Formula One circuit, Al Shallal Theme Park has long served as a premier entertainment destination for local families and visitors. Through the deployment, VENU+ will implement its proprietary GoPod® locker system, enabling guests to seamlessly rent and access lockers through the company’s integrated software platform under a revenue-sharing model with the park.
“The attractions industry is evolving rapidly as operators seek more seamless, technology-enabled ways to engage today’s guests,” said John Dunlap, Chief Executive Officer of VENU+. “As tourism and experiential entertainment continue expanding globally, VENU+ is uniquely positioned to help destinations modernize infrastructure, elevate the guest journey, and create more connected, efficient, and personalized experiences at scale.”
The announcement follows a series of recent milestones for VENU+ across the Middle East and other rapidly expanding tourism markets. In neighboring Bahrain, the company recently completed deployment of its GoPod® Locker technology at Janat Dilmun Waterpark, while additional projects remain underway across the region, including a major new waterpark development in Dubai expected to open later this year.
As attractions operators increasingly prioritize convenience and frictionless guest engagement, VENU+ continues investing in technologies designed to modernize venue infrastructure and reimagine the guest experience across entertainment destinations worldwide.
The deployment at Al Shallal Theme Park reflects continued momentum behind VENU+’s global growth strategy as the company expands into high-opportunity markets and continues developing next-generation technologies designed to meet the evolving expectations of modern consumers and destination operators alike.
About VENU+
VENU+ is the world’s leading provider of full-service, tech-enabled solutions that generate revenue and improve the guest experience for entertainment destinations worldwide. Its offerings include guest mobility, smart lockers, souvenir coins, photo capture, and entertainment solutions. VENU+ operates in all 50 U.S. states and across 13 countries on four continents, setting the global standard for world-class products and services for more than 42 years.
VENU+ is backed by ZCG Private Equity, the private equity arm of Z Capital Group, LLC (“ZCG”), a leading, privately held global firm.
About ZCG
ZCG is a leading, privately held global firm comprised of private markets asset management, business consulting services, and technology development and solutions. ZCG’s investors include pension funds, endowments, foundations, sovereign wealth funds, central banks, and insurance companies. For almost 30 years, ZCG Principals have invested tens of billions of dollars of capital. ZCG has approximately 400 professionals across five countries and is headquartered in New York. For more information, visit www.zcg.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260617240101/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom